SCHEMBL1780244

SCHEMBL1780244

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)c2cnoc2C)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
TP53 P04637 4/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
CSF1R P07333 1/20 0.36
TSHR P16473 4/20 0.36
POLB P06746 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 4/20 0.36
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAPT P10636 1/20 0.35
USP2 O75604 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779174 0.91 RAB9A (0.39) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1779652 0.88 RXFP1 (0.36) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1777881 0.86 HSD17B10 (0.35) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1780033 0.86 KDM4E (0.44) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1778870 0.86 CSF1R (0.40) GAACSF1RKMT2AMEN1
SCHEMBL1778268 0.85 ALDH1A1 (0.39) HSD17B10ALDH1A1GAATP53TSHR
SCHEMBL4592913 0.85 ITGA4 (0.34) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1781046 0.85 ALDH1A1 (0.38) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1780565 0.84 ALDH1A1 (0.40) HSD17B10ALDH1A1GAATP53RAB9A
SCHEMBL1777784 0.83 KDM4E (0.41) HSD17B10ALDH1A1GAATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 HSD17B10 2498/4885ALDH1A1 3557/4885GAA 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.